Mechanism-directed combinational immunotherapies in liver cancer hold promise.
作者信息
Marshall Gregory, Cao Jian
机构信息
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, 08901, USA.
Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ, 08901, USA.
出版信息
Cell Mol Immunol. 2023 Nov;20(11):1395-1397. doi: 10.1038/s41423-023-01068-z. Epub 2023 Aug 7.
Abstract
摘要
相似文献
1
Mechanism-directed combinational immunotherapies in liver cancer hold promise.
Cell Mol Immunol. 2023 Nov;20(11):1395-1397. doi: 10.1038/s41423-023-01068-z. Epub 2023 Aug 7.
2
Editorial: Immunotherapy and small molecule inhibitors as combinational cancer therapeutics.
Front Immunol. 2023 Aug 22;14:1270182. doi: 10.3389/fimmu.2023.1270182. eCollection 2023.
3
Editorial: Combinational immunotherapy of cancer: novel targets, mechanisms, and strategies.
Front Immunol. 2023 Aug 11;14:1250975. doi: 10.3389/fimmu.2023.1250975. eCollection 2023.
4
Editorial: Community series in combinational immunotherapy of cancer: novel targets, mechanisms, and strategies, volume II.
Front Immunol. 2023 Aug 11;14:1256691. doi: 10.3389/fimmu.2023.1256691. eCollection 2023.
5
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment.
Front Immunol. 2024 Sep 3;15:1460282. doi: 10.3389/fimmu.2024.1460282. eCollection 2024.
6
Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.
Front Immunol. 2022 Nov 23;13:1033000. doi: 10.3389/fimmu.2022.1033000. eCollection 2022.
7
The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.
Oncoimmunology. 2019 Oct 13;9(1):1673129. doi: 10.1080/2162402X.2019.1673129. eCollection 2020.
8
The State of Immunotherapy in Hepatobiliary Cancers.
Cells. 2021 Aug 15;10(8):2096. doi: 10.3390/cells10082096.
9
Liver specific gene immunotherapies resolve immune suppressive ectopic lymphoid structures of liver metastases and prolong survival.
Biomaterials. 2017 Oct;141:260-271. doi: 10.1016/j.biomaterials.2017.07.007. Epub 2017 Jul 6.
10
Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer.
Int J Mol Sci. 2023 Jul 13;24(14):11387. doi: 10.3390/ijms241411387.
引用本文的文献
1
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.
Oncol Rep. 2024 Dec;52(6). doi: 10.3892/or.2024.8831. Epub 2024 Oct 25.
本文引用的文献
1
Elevated nuclear PIGL disrupts the cMyc/BRD4 axis and improves PD-1 blockade therapy by dampening tumor immune evasion.
Cell Mol Immunol. 2023 Aug;20(8):867-880. doi: 10.1038/s41423-023-01048-3. Epub 2023 Jun 7.
2
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
3
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.
Clin Cancer Res. 2022 Jun 1;28(11):2449-2460. doi: 10.1158/1078-0432.CCR-21-2517.
4
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Hepatology. 2021 Nov;74(5):2652-2669. doi: 10.1002/hep.32023. Epub 2021 Sep 27.
5
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001435.
6
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
Exp Mol Med. 2020 Sep;52(9):1475-1485. doi: 10.1038/s12276-020-00500-y. Epub 2020 Sep 11.
7
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.
Clin Cancer Res. 2019 Jul 15;25(14):4530-4541. doi: 10.1158/1078-0432.CCR-18-2840. Epub 2019 Apr 2.
8
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
J Hepatol. 2015 Apr;62(4):863-70. doi: 10.1016/j.jhep.2014.11.011. Epub 2014 Nov 22.
9
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
PLoS One. 2014 Oct 15;9(10):e109992. doi: 10.1371/journal.pone.0109992. eCollection 2014.
Zotero 插件